IGHA1 and infection: The Ad26.RSV.preF/RSV preF protein combination vaccine is differentiated from RSV preF protein alone by its more robust RSV preF-specific IgA1 and IgM responses and the de novo induction of RSV preF-specific antibodies, all of which are known to be correlated with reduced infection risk (22).